In vivo intervention with the p-Erk1/2 antagonist U0126 in the pregnant VDD mice model at E10.5 improved CAKUT occurrence in offspring with p-Erk1/2 expression decreasing toward normal levels. The gene discussed is MAPK3; the disease is congenital anomaly of kidney and urinary tract.